Comparison of pulsatile subcutaneous gonadotropin-releasing hormone and exogenous gonadotropins in the treatment of men with isolated hypogonadotropic hypogonadism.
Eight men with isolated hypogonadotropic hypogonadism were treated with pulsatile gonadotropin-releasing hormone (GnRH) after maximal testicular growth and function had already been achieved with human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG). Only four subjects could normalize plasma testosterone (T) levels (group A). After 18 months of GnRH therapy, testicular size of group A increased by 53% (P less than 0.01) over that previously attained with exogenous gonadotropins. However, despite further testicular growth, two men who were previously azoospermic on hCG/hMG remained so on GnRH. In the other two patients, total sperm count increased minimally. Thus, pulsatile gonadotropin levels achieved with GnRH are more effective in stimulating testicular growth, but not necessarily sperm output, than are stable gonadotropin concentrations obtained with hCG/hMG.
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D007260:Infusion Pumps; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D010906:Pituitary Hormone-Releasing Hormones / Q000008:administration & dosage* / Q000627:therapeutic use; D013091:Spermatogenesis / Q000187:drug effects; D013268:Stimulation, Chemical; D013737:Testis / Q000254:growth & development; D013739:Testosterone / Q000378:metabolism; D013997:Time Factors
D006063:Chorionic Gonadotropin; D010906:Pituitary Hormone-Releasing Hormones; D013739:Testosterone; D008596:Menotropins